GW Pharmaceuticals PLC- Stock Price, News & Analysis (NASDAQ:GWPH)

$132.43 2.13 (1.63 %)
(As of 01/18/2018 11:07 AM ET)
Previous Close$130.30
Today's Range$130.30 - $134.11
52-Week Range$92.65 - $140.52
Volume542,500 shs
Average Volume415,145 shs
Market Capitalization$3.37 billion
P/E Ratio-18.39
Dividend YieldN/A
Beta2.65

About GW Pharmaceuticals PLC- (NASDAQ:GWPH)

GW Pharmaceuticals PLC- logoGW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the Company's commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.

Receive GWPH News and Ratings via Email

Sign-up to receive the latest news and ratings for GWPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:GWPH
CUSIPN/A
Phone+44-1223-266800

Debt

Debt-to-Equity Ratio0.02%
Current Ratio7.59%
Quick Ratio7.47%

Price-To-Earnings

Trailing P/E Ratio-18.3930555555556
Forward P/E Ratio-16.91
P/E GrowthN/A

Sales & Book Value

Annual Sales$11 million
Price / Sales334.33
Cash FlowN/A
Price / CashN/A
Book Value$13.92 per share
Price / Book9.51

Profitability

Trailing EPS($7.20)
Net Income$-166,900,000.00
Net Margins-1,607.85%
Return on Equity-40.42%
Return on Assets-34.97%

Miscellaneous

Employees583
Outstanding Shares27,770,000

GW Pharmaceuticals PLC- (NASDAQ:GWPH) Frequently Asked Questions

What is GW Pharmaceuticals PLC-'s stock symbol?

GW Pharmaceuticals PLC- trades on the NASDAQ under the ticker symbol "GWPH."

How were GW Pharmaceuticals PLC-'s earnings last quarter?

GW Pharmaceuticals PLC- (NASDAQ:GWPH) issued its quarterly earnings data on Monday, December, 4th. The biopharmaceutical company reported ($2.18) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.73) by $0.45. GW Pharmaceuticals PLC- had a negative net margin of 1,607.85% and a negative return on equity of 40.42%. View GW Pharmaceuticals PLC-'s Earnings History.

When will GW Pharmaceuticals PLC- make its next earnings announcement?

GW Pharmaceuticals PLC- is scheduled to release their next quarterly earnings announcement on Tuesday, February, 6th 2018. View Earnings Estimates for GW Pharmaceuticals PLC-.

Where is GW Pharmaceuticals PLC-'s stock going? Where will GW Pharmaceuticals PLC-'s stock price be in 2018?

8 brokerages have issued 12 month price targets for GW Pharmaceuticals PLC-'s shares. Their forecasts range from $61.00 to $208.00. On average, they expect GW Pharmaceuticals PLC-'s share price to reach $152.50 in the next year. View Analyst Ratings for GW Pharmaceuticals PLC-.

What are Wall Street analysts saying about GW Pharmaceuticals PLC- stock?

Here are some recent quotes from research analysts about GW Pharmaceuticals PLC- stock:

  • 1. According to Zacks Investment Research, "GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. " (1/9/2018)
  • 2. Cantor Fitzgerald analysts commented, "Tonight (11/20), the American Epilepsy Society (AES) published the abstracts for the upcoming annual meeting in early December." (11/20/2017)
  • 3. Maxim Group analysts commented, "GW pharmaceuticals announced publication of data from the P3 study of Epidiolex (oral CBD, cannabidiol) in pediatric Dravet Syndrome in The New England Journal of Medicine (NEJM)." (5/25/2017)

Who are some of GW Pharmaceuticals PLC-'s key competitors?

Who are GW Pharmaceuticals PLC-'s key executives?

GW Pharmaceuticals PLC-'s management team includes the folowing people:

  • Geoffrey W. Guy, Executive Chairman of the Board (Age 60)
  • Justin Gover, Chief Executive Officer, Director (Age 43)
  • Adam David George, Chief Financial Officer, Company Secretary, Director (Age 44)
  • Christopher John Tovey, Chief Operating Officer, Executive Director (Age 49)
  • Julian S. Gangolli, Executive Director (Age 59)
  • James Julian Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director (Age 55)
  • Cabot Brown, Non-Executive Independent Director (Age 53)
  • Thomas Gerard Lynch, Non-Executive Independent Director (Age 58)
  • Catherine J. Mackey Ph.D., Non-Executive Independent Director (Age 61)
  • Alicia Secor, Non-Executive Independent Director (Age 54)

Who owns GW Pharmaceuticals PLC- stock?

GW Pharmaceuticals PLC-'s stock is owned by many different of institutional and retail investors. Top institutional investors include Creative Planning (0.02%) and Bank of Montreal Can (0.01%). View Institutional Ownership Trends for GW Pharmaceuticals PLC-.

Who bought GW Pharmaceuticals PLC- stock? Who is buying GW Pharmaceuticals PLC- stock?

GW Pharmaceuticals PLC-'s stock was acquired by a variety of institutional investors in the last quarter, including Creative Planning and Bank of Montreal Can. View Insider Buying and Selling for GW Pharmaceuticals PLC-.

How do I buy GW Pharmaceuticals PLC- stock?

Shares of GW Pharmaceuticals PLC- can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GW Pharmaceuticals PLC-'s stock price today?

One share of GW Pharmaceuticals PLC- stock can currently be purchased for approximately $132.43.

How big of a company is GW Pharmaceuticals PLC-?

GW Pharmaceuticals PLC- has a market capitalization of $3.37 billion and generates $11 million in revenue each year. The biopharmaceutical company earns $-166,900,000.00 in net income (profit) each year or ($7.20) on an earnings per share basis. GW Pharmaceuticals PLC- employs 583 workers across the globe.

How can I contact GW Pharmaceuticals PLC-?

GW Pharmaceuticals PLC-'s mailing address is Sovereign House, Vision Park, CAMBRIDGE, 00000, United Kingdom. The biopharmaceutical company can be reached via phone at +44-1223-266800 or via email at [email protected]


MarketBeat Community Rating for GW Pharmaceuticals PLC- (GWPH)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  366 (Vote Outperform)
Underperform Votes:  149 (Vote Underperform)
Total Votes:  515
MarketBeat's community ratings are surveys of what our community members think about GW Pharmaceuticals PLC- and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

GW Pharmaceuticals PLC- (NASDAQ:GWPH) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.882.882.712.88
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $152.50$152.50$144.57$161.71
Price Target Upside: 23.00% upside23.00% upside26.18% upside71.78% upside

GW Pharmaceuticals PLC- (NASDAQ:GWPH) Consensus Price Target History

Price Target History for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

GW Pharmaceuticals PLC- (NASDAQ:GWPH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/14/2017Goldman Sachs GroupUpgradeNeutral -> Buy$174.00MediumView Rating Details
12/4/2017Cantor FitzgeraldSet Price TargetBuy$208.00HighView Rating Details
11/14/2017Bank of AmericaLower Price TargetBuy$160.00 -> $158.00N/AView Rating Details
10/2/2017CowenReiterated RatingOutperform$165.00MediumView Rating Details
10/2/2017Leerink SwannReiterated RatingOutperform$160.00 -> $153.00MediumView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$154.00MediumView Rating Details
8/8/2017Maxim GroupDowngradeBuy -> Hold$61.00HighView Rating Details
2/7/2017Piper Jaffray CompaniesSet Price TargetBuy$147.00N/AView Rating Details
9/25/2016Morgan StanleyBoost Price TargetOverweight$152.00 -> $160.00N/AView Rating Details
8/26/2016Numis SecuritiesUpgradeSell -> HoldN/AView Rating Details
6/27/2016Janney Montgomery ScottInitiated CoverageSell$40.00N/AView Rating Details
3/14/2016Roth CapitalBoost Price TargetBuy$130.00 -> $160.00N/AView Rating Details
(Data available from 1/18/2016 forward)

Earnings

GW Pharmaceuticals PLC- (NASDAQ:GWPH) Earnings History and Estimates Chart

Earnings by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

GW Pharmaceuticals PLC- (NASDAQ GWPH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/6/2018        
12/4/2017Q4 2017($1.73)($2.18)ViewN/AView Earnings Details
8/7/20176/30/2017($1.73)($2.07)$2.10 million$3.14 millionViewListenView Earnings Details
5/9/20173/31/2017($1.50)($1.70)$2.07 million$2.04 millionViewListenView Earnings Details
2/7/2017Q117($1.35)($0.77)$1.85 million$2.54 millionViewListenView Earnings Details
12/5/2016Q416($1.48)($0.89)$2.85 million$2.16 millionViewListenView Earnings Details
8/9/2016Q3 2016($1.73)($0.73)ViewN/AView Earnings Details
5/5/2016Q2 2016($1.71)($1.10)ViewN/AView Earnings Details
2/10/2016Q116($1.53)($0.10)$4.61 million$5.40 millionViewListenView Earnings Details
12/7/2015Q415($1.38)($0.85)$15.00 million$5.60 millionViewN/AView Earnings Details
8/6/2015Q315($1.30)($1.60)$12.82 million$13.55 millionViewN/AView Earnings Details
5/11/2015Q215($1.23)($0.58)$11.38 million$9.43 millionViewListenView Earnings Details
2/4/2015Q115($0.91)($0.26)$12.12 million$12.40 millionViewN/AView Earnings Details
12/2/2014Q414($0.46)$0.02$9.15 million$12.03 millionViewN/AView Earnings Details
8/6/2014Q314($0.62)($0.66)$12.88 million$13.00 millionViewN/AView Earnings Details
5/7/2014Q114($0.30)$0.49$12.48 million$12.55 millionViewN/AView Earnings Details
2/4/2014Q413($0.34)($0.02)$11.54 million$7.49 millionViewN/AView Earnings Details
11/19/2013Q4($0.19)($0.29)ViewListenView Earnings Details
8/5/2013Q313($0.11)$0.02$10.71 million$11.04 millionViewN/AView Earnings Details
6/3/2013Q2 2013($0.26)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

GW Pharmaceuticals PLC- (NASDAQ:GWPH) Earnings Estimates

Current Year EPS Consensus Estimate: $-7.83 EPS
Next Year EPS Consensus Estimate: $-0.51 EPS

Dividends

Dividend History for GW Pharmaceuticals PLC- (NASDAQ:GWPH)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for GW Pharmaceuticals PLC- (NASDAQ GWPH)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

GW Pharmaceuticals PLC- (NASDAQ GWPH) News Headlines

Source:
DateHeadline
Zacks: Analysts Expect GW Pharmaceuticals PLC- (GWPH) Will Announce Quarterly Sales of $2.14 MillionZacks: Analysts Expect GW Pharmaceuticals PLC- (GWPH) Will Announce Quarterly Sales of $2.14 Million
www.americanbankingnews.com - January 18 at 9:40 AM
5 Weed Stocks To Watch In 20185 Weed Stocks To Watch In 2018
www.benzinga.com - January 17 at 3:19 PM
Pot Stocks & ETFs: This Weeks Top News In The Cannabis IndustryPot Stocks & ETFs: This Week's Top News In The Cannabis Industry
www.marketwatch.com - January 13 at 3:18 PM
GW Pharmaceuticals PLC- ADR Stock Is Set for a STRONG Comeback - Investorplace.comGW Pharmaceuticals PLC- ADR Stock Is Set for a STRONG Comeback - Investorplace.com
investorplace.com - January 13 at 6:34 AM
GW Pharmaceuticals PLC- ADR Stock Is Set for a STRONG ComebackGW Pharmaceuticals PLC- ADR Stock Is Set for a STRONG Comeback
investorplace.com - January 12 at 7:37 AM
What's Behind This Marijuana Stock Soaring 81.5% in December?What's Behind This Marijuana Stock Soaring 81.5% in December?
finance.yahoo.com - January 6 at 7:31 AM
Epidiolex Approval Does Not Make GW Pharmaceuticals A Buy - Seeking AlphaEpidiolex Approval Does Not Make GW Pharmaceuticals A Buy - Seeking Alpha
seekingalpha.com - January 3 at 3:19 PM
January Top Growth StocksJanuary Top Growth Stocks
finance.yahoo.com - January 3 at 11:15 AM
Here Is the Buzz on My Under-the-Radar Top ETF Pick for 2018Here Is the Buzz on My Under-the-Radar Top ETF Pick for 2018
finance.yahoo.com - January 2 at 3:20 PM
Wired News – FDA Accepted GW Pharmas NDA Filing for Epidiolex(R) in the Treatment of Lennox-Gastaut Syndrome and Dravet SyndromeWired News – FDA Accepted GW Pharma's NDA Filing for Epidiolex(R) in the Treatment of Lennox-Gastaut Syndrome and Dravet Syndrome
finance.yahoo.com - January 2 at 3:20 PM
Biotech Stock Trades and Mergers to Watch in 2018Biotech Stock Trades and Mergers to Watch in 2018
finance.yahoo.com - January 2 at 3:20 PM
GW Pharmaceuticals PLC- (GWPH) vs. Gemphire Therapeutics (GEMP) Head to Head ContrastGW Pharmaceuticals PLC- (GWPH) vs. Gemphire Therapeutics (GEMP) Head to Head Contrast
www.americanbankingnews.com - January 1 at 7:16 PM
GW Pharmaceuticals Plc :GWPH-US: Earnings Analysis: Q4, 2017 By the Numbers : January 1, 2018GW Pharmaceuticals Plc :GWPH-US: Earnings Analysis: Q4, 2017 By the Numbers : January 1, 2018
finance.yahoo.com - January 1 at 3:19 PM
Zacks: Analysts Anticipate GW Pharmaceuticals PLC- (GWPH) Will Announce Quarterly Sales of $2.14 MillionZacks: Analysts Anticipate GW Pharmaceuticals PLC- (GWPH) Will Announce Quarterly Sales of $2.14 Million
www.americanbankingnews.com - January 1 at 10:52 AM
Zacks: Brokerages Expect GW Pharmaceuticals PLC- (GWPH) to Post -$1.95 Earnings Per ShareZacks: Brokerages Expect GW Pharmaceuticals PLC- (GWPH) to Post -$1.95 Earnings Per Share
www.americanbankingnews.com - December 30 at 1:18 PM
GW Pharmas cannabis-derived drug to be reviewed by FDA - MarketWatchGW Pharma's cannabis-derived drug to be reviewed by FDA - MarketWatch
www.marketwatch.com - December 30 at 6:29 AM
GW Pharma (GWPH) Submits MAA in Europe for Epidiolex for Lennox-Gastaut Syndrome and Dravet Syndrome - StreetInsider.comGW Pharma (GWPH) Submits MAA in Europe for Epidiolex for Lennox-Gastaut Syndrome and Dravet Syndrome - StreetInsider.com
www.streetinsider.com - December 30 at 6:29 AM
Stock Update (NASDAQ:GWPH): GW Pharmaceuticals PLC- ADR Has Eyes on Marketing Lead Cannabinoid Asset in EuropeStock Update (NASDAQ:GWPH): GW Pharmaceuticals PLC- ADR Has Eyes on Marketing Lead Cannabinoid Asset in Europe
finance.yahoo.com - December 29 at 9:24 AM
GW Pharma (GWPH) Announces FDA Acceptance for Epidiolex NDA with Priority Review for Lennox-Gastaut Syndrome and Dravet SyndromeGW Pharma (GWPH) Announces FDA Acceptance for Epidiolex NDA with Priority Review for Lennox-Gastaut Syndrome and Dravet Syndrome
www.streetinsider.com - December 28 at 4:31 PM
ETFs with exposure to GW Pharmaceuticals Plc : December 28, 2017ETFs with exposure to GW Pharmaceuticals Plc : December 28, 2017
finance.yahoo.com - December 28 at 4:31 PM
GW Pharmas cannabis-derived drug to be reviewed by FDAGW Pharma's cannabis-derived drug to be reviewed by FDA
finance.yahoo.com - December 28 at 4:31 PM
Stock Update (NASDAQ:GWPH): GW Pharmaceuticals PLC- ADR NDA Filing for Epidiolex Garners FDA Priority ReviewStock Update (NASDAQ:GWPH): GW Pharmaceuticals PLC- ADR NDA Filing for Epidiolex Garners FDA Priority Review
finance.yahoo.com - December 28 at 4:31 PM
GW Pharmaceuticals Announces Acceptance of NDA Filing for Epidiolex® (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndromeGW Pharmaceuticals Announces Acceptance of NDA Filing for Epidiolex® (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndrome
finance.yahoo.com - December 28 at 4:31 PM
Has The Crypto Craze Killed The Marijuana Investing Buzz?Has The Crypto Craze Killed The Marijuana Investing Buzz?
www.benzinga.com - December 27 at 8:07 PM
GW Pharmaceuticals PLC- (GWPH) Rating Lowered to Sell at Zacks Investment ResearchGW Pharmaceuticals PLC- (GWPH) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - December 26 at 11:32 PM
GW Pharmaceuticals PLC- (GWPH) Receives Average Rating of "Buy" from AnalystsGW Pharmaceuticals PLC- (GWPH) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - December 26 at 1:38 AM
Benzingas Bulls & Bears: Looking Back, Looking Forward - BenzingaBenzinga's Bulls & Bears: Looking Back, Looking Forward - Benzinga
www.benzinga.com - December 24 at 3:25 PM
Can This Beaten-Down Marijuana Stock Roar Back in 2018?Can This Beaten-Down Marijuana Stock Roar Back in 2018?
finance.yahoo.com - December 23 at 3:30 PM
GW Pharmaceuticals PLC- (GWPH) Stock Rating Upgraded by BidaskClubGW Pharmaceuticals PLC- (GWPH) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - December 22 at 9:04 PM
2018's 3 Biggest Catalysts for Marijuana Stocks2018's 3 Biggest Catalysts for Marijuana Stocks
finance.yahoo.com - December 22 at 3:30 PM
GW Pharma (GWPH) Appoints Catherine Mackey, Alicia Secor and ... - StreetInsider.comGW Pharma (GWPH) Appoints Catherine Mackey, Alicia Secor and ... - StreetInsider.com
www.streetinsider.com - December 22 at 6:28 AM
3 Best Marijuana Biotech Stocks for 20183 Best Marijuana Biotech Stocks for 2018
finance.yahoo.com - December 22 at 6:28 AM
Financial Survey: GW Pharmaceuticals PLC- (GWPH) versus Its PeersFinancial Survey: GW Pharmaceuticals PLC- (GWPH) versus Its Peers
www.americanbankingnews.com - December 20 at 7:10 PM
GW Pharmaceuticals Earns Relative Strength Rating Upgrade; Hits Key BenchmarkGW Pharmaceuticals Earns Relative Strength Rating Upgrade; Hits Key Benchmark
finance.yahoo.com - December 17 at 3:18 PM
GW Pharmaceuticals (GWPH) Soars: Stock Adds 5.5% in Session - NasdaqGW Pharmaceuticals (GWPH) Soars: Stock Adds 5.5% in Session - Nasdaq
www.nasdaq.com - December 16 at 3:18 PM
 Analysts Anticipate GW Pharmaceuticals PLC- (GWPH) Will Post Quarterly Sales of $2.14 Million Analysts Anticipate GW Pharmaceuticals PLC- (GWPH) Will Post Quarterly Sales of $2.14 Million
www.americanbankingnews.com - December 15 at 12:58 PM
Goldman Sachs Sees 40% Upside In GW Pharmaceuticals - BenzingaGoldman Sachs Sees 40% Upside In GW Pharmaceuticals - Benzinga
www.benzinga.com - December 15 at 6:18 AM
GW Pharmaceuticals PLC- (GWPH) Lifted to "Buy" at Goldman Sachs GroupGW Pharmaceuticals PLC- (GWPH) Lifted to "Buy" at Goldman Sachs Group
www.americanbankingnews.com - December 14 at 10:38 PM
Goldman Sachs Sees 40% Upside In GW PharmaceuticalsGoldman Sachs Sees 40% Upside In GW Pharmaceuticals
finance.yahoo.com - December 14 at 3:19 PM
GW Pharmaceuticals Trying To Close In On Key Technical BenchmarkGW Pharmaceuticals Trying To Close In On Key Technical Benchmark
finance.yahoo.com - December 14 at 3:19 PM
GW Pharma (GWPH) Says Otsuka License Agreement on Sativex ... - StreetInsider.comGW Pharma (GWPH) Says Otsuka License Agreement on Sativex ... - StreetInsider.com
www.streetinsider.com - December 14 at 6:24 AM
 Analysts Anticipate GW Pharmaceuticals PLC- (GWPH) to Announce -$2.10 EPS Analysts Anticipate GW Pharmaceuticals PLC- (GWPH) to Announce -$2.10 EPS
www.americanbankingnews.com - December 13 at 9:24 AM
GW Pharmaceuticals plc Announces the Closing of Public Offering of ADSs Raising Gross Proceeds of $GW Pharmaceuticals plc Announces the Closing of Public Offering of ADSs Raising Gross Proceeds of $
www.nasdaq.com - December 12 at 3:18 PM
GW Pharmaceuticals plc Announces the Closing of Public Offering ... - GlobeNewswire (press release)GW Pharmaceuticals plc Announces the Closing of Public Offering ... - GlobeNewswire (press release)
globenewswire.com - December 12 at 6:25 AM
GW Pharmaceuticals PLC- (GWPH) and Its Competitors Financial SurveyGW Pharmaceuticals PLC- (GWPH) and Its Competitors Financial Survey
www.americanbankingnews.com - December 9 at 5:28 PM
Analysts Issue Forecasts for GW Pharmaceuticals PLC-s FY2018 Earnings (GWPH)Analysts Issue Forecasts for GW Pharmaceuticals PLC-'s FY2018 Earnings (GWPH)
www.americanbankingnews.com - December 8 at 12:34 PM
GW Pharma (GWPH) Prices 2.4M ADS Offering at $115/ShGW Pharma (GWPH) Prices 2.4M ADS Offering at $115/Sh
www.streetinsider.com - December 7 at 3:19 PM
ETFs with exposure to GW Pharmaceuticals Plc : December 7, 2017ETFs with exposure to GW Pharmaceuticals Plc : December 7, 2017
finance.yahoo.com - December 7 at 3:19 PM
GW Pharmaceuticals: A Desirable Mix Of Value And Catalysts - Seeking AlphaGW Pharmaceuticals: A Desirable Mix Of Value And Catalysts - Seeking Alpha
seekingalpha.com - December 7 at 6:37 AM
GW Pharma Results Set Up A Key 2019 - Seeking AlphaGW Pharma Results Set Up A Key 2019 - Seeking Alpha
seekingalpha.com - December 7 at 6:37 AM

SEC Filings

GW Pharmaceuticals PLC- (NASDAQ:GWPH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

GW Pharmaceuticals PLC- (NASDAQ:GWPH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

GW Pharmaceuticals PLC- (NASDAQ GWPH) Stock Chart for Thursday, January, 18, 2018

Loading chart…

This page was last updated on 1/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.